Management of Non-Urticarial Rash After Cephalosporin Exposure

Understanding the Clinical Scenario

A non-urticarial rash developing 2 days after cephalosporin exposure indicates a delayed-type hypersensitivity reaction, and both penicillins and cephalosporins with similar R1 side chains should be avoided, while cephalosporins with dissimilar side chains, carbapenems, and monobactams can be safely administered without prior testing, as recommended by the Journal of Allergy and Clinical Immunology 1, 2, 3
The timing and non-urticarial nature of the rash exclude immediate-type reactions, and these delayed reactions do not fall under the severe cutaneous adverse reactions category, according to the Journal of Allergy and Clinical Immunology 1, 2, 3

The Dutch Working Party on Antibiotic Policy (SWAB) guidelines recommend avoiding all penicillins if the reaction occurred within the past year, and considering penicillins if the reaction occurred more than 1 year ago, with caution still warranted 3
Cephalosporins with similar R1 side chains to common penicillins, such as cephalexin, cefaclor, and cefamandole, should be avoided, while cephalosporins with dissimilar R1 side chains, such as cefazolin, cefpodoxime, and ceftriaxone, can be safely used, as recommended by the Journal of Allergy and Clinical Immunology 1, 2, 3
Carbapenems and monobactams can be administered without prior testing or additional precautions, with a cross-reactivity risk of only 0.87% for carbapenems in penicillin-allergic patients, according to the Journal of Allergy and Clinical Immunology 6

Penicillin skin testing is not necessary for patients with non-anaphylactic cephalosporin allergy, and is reserved for patients with anaphylaxis, angioedema, or severe IgE-mediated reactions to cephalosporins, as recommended by the Journal of Allergy and Clinical Immunology 1, 6
The assumption of 10% cross-reactivity between penicillins and cephalosporins is outdated and has been refuted, with modern cross-reactivity rates ranging from 2-4.8% for confirmed allergies, according to the Journal of Allergy and Clinical Immunology 1, 2, 7
Avoiding all beta-lactams unnecessarily can lead to increased patient morbidity, mortality, and healthcare costs, and should be avoided, as recommended by the Journal of Allergy and Clinical Immunology and the Dutch Working Party on Antibiotic Policy (SWAB) 1, 3, 6